DaVita (NYSE:DVA) Updates FY24 Earnings Guidance

DaVita (NYSE:DVA) updated its FY24 earnings guidance on Thursday. The company provided earnings per share guidance of $9.00-$9.80 for the period, compared to the consensus earnings per share estimate of $9.30.

Analysts Set New Price Targets

Several equities research analysts have commented on DVA shares. TheStreet upgraded DaVita from a c+ rating to a b- rating in a research note on Wednesday, February 7th. Truist Financial boosted their target price on DaVita from $130.00 to $135.00 and gave the company a hold rating in a research note on Tuesday, February 20th. UBS Group boosted their target price on DaVita from $113.00 to $134.00 and gave the company a buy rating in a research note on Wednesday, February 14th. Barclays started coverage on DaVita in a research note on Wednesday, March 6th. They issued an equal weight rating and a $133.00 target price on the stock. Finally, StockNews.com upgraded DaVita from a buy rating to a strong-buy rating in a research note on Thursday, April 25th. Two research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of Moderate Buy and a consensus price target of $118.50.

DaVita Stock Down 5.5 %

Shares of DaVita stock traded down $7.79 on Friday, reaching $134.45. 2,541,405 shares of the company were exchanged, compared to its average volume of 628,593. DaVita has a one year low of $71.51 and a one year high of $145.04. The company has a market capitalization of $11.79 billion, a price-to-earnings ratio of 15.28, a PEG ratio of 1.20 and a beta of 1.04. The company has a current ratio of 1.19, a quick ratio of 1.13 and a debt-to-equity ratio of 6.65. The company has a 50-day moving average of $133.71 and a 200 day moving average of $112.84.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Thursday, May 2nd. The company reported $2.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.95 by $0.43. DaVita had a return on equity of 66.59% and a net margin of 6.61%. The company had revenue of $3.07 billion for the quarter, compared to analysts’ expectations of $3.03 billion. During the same quarter in the prior year, the business posted $1.58 EPS. The business’s revenue was up 6.9% compared to the same quarter last year. On average, equities research analysts forecast that DaVita will post 9.49 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO Javier Rodriguez sold 67,603 shares of the stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $126.11, for a total value of $8,525,414.33. Following the transaction, the chief executive officer now directly owns 488,697 shares of the company’s stock, valued at $61,629,578.67. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CEO Javier Rodriguez sold 67,603 shares of the company’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $126.11, for a total value of $8,525,414.33. Following the transaction, the chief executive officer now directly owns 488,697 shares in the company, valued at $61,629,578.67. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Michael David Staffieri sold 29,488 shares of the stock in a transaction that occurred on Wednesday, February 21st. The stock was sold at an average price of $119.81, for a total transaction of $3,532,957.28. Following the transaction, the chief operating officer now owns 37,687 shares in the company, valued at approximately $4,515,279.47. The disclosure for this sale can be found here. In the last three months, insiders have sold 134,540 shares of company stock valued at $16,551,071. 1.40% of the stock is owned by insiders.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.